INTRODUCTION {#S1}
============

Acyl coenzyme A (CoA) molecules, which hold a prominent position in mitochondrial metabolism as intermediates of fuel oxidation, fluctuate in response to energy supply and demand. Accumulation of acyl CoAs within the mitochondrial matrix gives rise to increased production of their cognate acyl-carnitine conjugates through the action of carnitine acyltransferase enzymes. Numerous studies have identified elevated tissue and plasma levels of acyl CoAs and/or acylcarnitines in the context of a wide variety of metabolic disorders, including obesity, diabetes, and heart failure, and inborn errors of metabolism ([@R40]; [@R47]). Because acyl CoAs are reactive and potentially toxic at high levels ([@R61]; [@R63]), this class of metabolites has been directly implicated in carbon-induced mitochondrial stress. One theory gaining strong traction suggests acyl CoA molecules disrupt mitochondrial function by serving as substrates for non-enzymatic acylation of proteins on the epsilon amino group of lysine residues ([@R64], [@R65], [@R66], [@R67]). This family of posttranslational modifications (PTMs) are prominently found on mitochondrial proteins ([@R30]), which are presumably more vulnerable to acylation because of the high acyl CoA content and slightly basic pH of the matrix ([@R12]; [@R32]; [@R49]; [@R51]; [@R62]). Accordingly, the detectable mitochondrial lysine acylome increases in the context of numerous metabolic diseases, including heart failure ([@R12]; [@R15]; [@R28]; [@R52]). These observations have led to the prevailing view that lysine acylation serves as a common mechanism by which carbon surplus disrupts protein function and/or quality, thereby compromising metabolic and respiratory reserve in a manner that increases organ susceptibility to energetic stress ([@R4]). The best evidence to support this theory comes from studies in mice lacking one or more of the mitochondrial sirtuins, a family of NAD^+^-dependent deacylases that includes SIRT3, the major mitochondrial deacetylase, and SIRT5, which acts as both a demalonylase and a desuccinylase. Although mice with deficiency of either SIRT3 or SIRT5 have modest phenotypes under basal conditions ([@R18]; [@R72]), they show increased susceptibility to metabolic insults, supporting a link between protein deacylation and stress resistance ([@R25]; [@R26]; [@R35]; [@R53]). Whereas these reports provide a conceptually satisfying model of nutrient-induced mitochondrial stress, direct evidence that protein acylation does indeed impose wide-ranging bioenergetic vulnerabilities remains sparse.

The current study sought to test the hypothesis that broad-ranging lysine hyperacylation of metabolic proteins leads to latent vulnerabilities in mitochondrial function and bioenergetics. To this end, we leveraged a recently developed mitochondrial diagnostics platform to comprehensively evaluate respiratory fluxes and energy transfer in mitochondria harvested from cardiac tissues with high relative levels of protein acylation due to genetically engineered enzyme deficiencies. Mice with heart- and muscle-specific malonyl CoA decarboxylase (MCD) deficiency were used to model inborn errors in metabolism that result in lysine acylation due to acyl CoA accumulation. MCD is predominately localized to the mitochondrial matrix, where it degrades malonyl-CoA to acetyl CoA. In humans with loss-of-function genetic mutations in the *MLYCD* gene, MCD enzyme inactivity results in marked accumulation of malonyl CoA and malonylcarnitine ([@R11]; [@R52]). Malonyl CoA is a particularly relevant molecule, because it is nutritionally regulated and more reactive than acetyl CoA ([@R34]), thus malonylation of mitochondrial proteins might underlie respiratory defects that contribute to cardiomyopathy in humans affected by MCD deficiency. Likewise, mice with transgenic knockout of *Sirt3* or *Sirt5* are predisposed to stress-induced heart failure, presumably due to PTMs that impede mitochondrial function ([@R26]; [@R28]; [@R31]). We therefore enlisted these two additional mouse lines as models of hyperacylation resulting from deacylase inactivity. Despite widespread hyperacylation of the mitochondrial proteome in all three models, the bioenergetic phenotypes observed in isolated mitochondria were inconsistent with broad-ranging respiratory insufficiencies.

RESULTS {#S2}
=======

Loss of MCD Increases Malonyl-CoA and Drives Lysine Malonylation {#S3}
----------------------------------------------------------------

Deficiency of MCD promotes lysine malonylation (K*mal*) in human fibroblasts ([@R11]). To investigate whether a similar phenomenon occurs in the heart, we bred mice harboring floxed alleles of the *Mlycd* gene (MCD^fl/fl^) with MCK-Cre transgenic mice to generate a muscle specific model of MCD deficiency (MCD^M−/−^) ([Figure S1](#SD1){ref-type="supplementary-material"}). Heart and skeletal muscle tissues from these mice were interrogated using flow injection tandem mass spectrometry (MS/MS)-based metabolic profiling. As anticipated, these assays revealed elevations in the isobaric peaks corresponding to malonyl/hydroxyisovaleryl-carnitine ([Figure 1A](#F1){ref-type="fig"}; indicated in red; [Figures S2A and S2B](#SD1){ref-type="supplementary-material"}) and malonyl/hydroxybutyryl-CoA ([Figure 1A](#F1){ref-type="fig"}; indicated in blue; [Figures S2C and S2D](#SD1){ref-type="supplementary-material"}), but little or no changes in other metabolites. Subsequent analyses via liquid chromatography-tandem mass spectrometry (LC-MS/MS) confirmed the identities of the metabolites accumulating in the MCD-deficient tissues as malonyl-CoA ([Figure 1B](#F1){ref-type="fig"}) and malonyl-carnitine ([Figure 1C](#F1){ref-type="fig"}), the latter of which is likely produced within the mitochondrial matrix. Consistent with these observations, subcellular fractionation experiments revealed that MCD is enriched in mitochondria ([Figure 1D](#F1){ref-type="fig"}). Elevated levels of malonyl CoA were accompanied by clear elevations in K*mal*, detected by immunoblot analyses performed with an anti-malonyl-lysine antibody (Cell Signaling; 14942S). These PTMs appeared to be enriched in the mitochondrial compartment, relative to the whole-cell lysate ([Figure S2H](#SD1){ref-type="supplementary-material"}). Protein expression of the SIRT5 demalonylase and desuccinlyase was unaffected by genotype ([Figure S3C](#SD1){ref-type="supplementary-material"}). Immunoblot analysis of K*mal* in liver and brain lysates from MCD^fl/fl^ or MCD^M−/−^ mice ([Figure S3D](#SD1){ref-type="supplementary-material"}) was also negative.

Whereas elevations in cytosolic malonyl CoA might be expected to oppose fatty acid oxidation by inhibiting carnitine palmitoyltrasnferase I (CPT1) ([@R42]), thereby lowering tissue levels of its long chain acylcarnitine products, we found little evidence for this effect ([Figures S2A and S2B](#SD1){ref-type="supplementary-material"}). Likewise, the whole-body metabolic phenotype of the mice was unremarkable ([Figures S3A and S3B](#SD1){ref-type="supplementary-material"}). These finding are consistent with previous studies in total body MCD knockout (KO) mice, which showed little impact of the deficiency when animals were fed *ad libitum* on a low-fat, standard chow diet ([@R32]; [@R60]). In light of this modest whole-body metabolic phenotype, the model was considered well suited for studies aimed at investigating the specific role of malonylation in regulating mitochondrial bioenergetics.

Identification of Malonylated Lysine Residues by nLC-MS/MS {#S4}
----------------------------------------------------------

To characterize the specific proteins and residues affected by malonylation, we performed isobaric tag-assisted quantitative malonyl-proteomics analysis of whole-cell lysates from heart and skeletal muscle of MCD^fl/fl^ and MCD^M−/−^ mice according to the workflow detailed in [Figure 1E](#F1){ref-type="fig"} and in the [STAR Methods](#S13){ref-type="sec"}. Of the \~407 unique malonylated peptides identified across both skeletal muscle and heart at a 1% false discovery rate (FDR), 227 unique malonylation sites within 85 proteins were found to be increased in MCD-deficient tissues (P~adjusted~ \< 0.1; [Table S1](#SD2){ref-type="supplementary-material"}). Fold changes for statistically significant hypermalonylation events ranged from quite small (\~1.4) to very large (\~293). The majority of the hypermalonylated peptides observed in the setting of MCD deficiency (heart; [Figure 1F](#F1){ref-type="fig"}, sk. muscle; [Figure S4A](#SD1){ref-type="supplementary-material"}; [Table S1](#SD2){ref-type="supplementary-material"}) mapped to proteins resident within the mitochondrial matrix ([Figure 1F](#F1){ref-type="fig"}; red data points represent mitochondrial targets) ([@R9]), consistent with the immunoblots ([Figure S2H](#SD1){ref-type="supplementary-material"}). When comparing hypermalonylated peptides identified in MCD^M−/−^ hearts versus skeletal muscle, we found 60% overlap at the protein level, but only 32% of unique malonylated peptides identified in each tissue shared a common lysine residue--likely due in part to the stochastic nature of shotgun proteomics data acquisition. Changes in mitochondrial K*mal* were not accompanied by global alterations in the proteome, assessed via nLC-MS/MS using the unenriched or "input" fractions from each tissue. Thus, other than MCD, only one (DECR1) of the other \~4,700 identified proteins was differentially expressed between MCD^fl/fl^ and MCD^M−/−^ tissues after adjusting for multiple hypothesis testing (P~adjusted~ \< 0.1). Therefore, increases in malonyl-peptide abundance following MCD deletion were not due to differences in protein expression (heart; [Figure 1G](#F1){ref-type="fig"}, sk. muscle; [Figure S4B](#SD1){ref-type="supplementary-material"}; [Table S1](#SD2){ref-type="supplementary-material"}). When adjustment for multiple hypothesis testing was restricted to the mitochondrial proteome, 13 proteins, all in heart tissue, were found to be differentially expressed at this same significance threshold (P~adjusted~ \< 0.1). Aside from DHRS1 and MCD, which were lower in MCD-deficient hearts, 6 of the 11 increasing proteins participate in mitochondrial beta-oxidation (ACOT2, CPT2, DECR1, DHRS1, ETFDH, and LYRM5). The proteomics results were consistent with immunoblots performed on mitochondrial lysates showing that electron transfer flavoprotein dehydrogenase (ETFDH; [Figures S4C and S4D](#SD1){ref-type="supplementary-material"}) and HADHA ([Figures S4C and S4F](#SD1){ref-type="supplementary-material"}) were modestly upregulated in MCD-deficient mitochondria, whereas the expression of ETFA and various ETS subunits were unchanged ([Figures S4C, S4E, S4G, and S4H](#SD1){ref-type="supplementary-material"}). Taken together, these data suggest the primary consequences of MCD deficiency within the muscle proteome is hypermalonylation of mitochondrial proteins. Proteins modified by malonylation were distributed throughout various mitochondrial pathways, including; acyl CoA metabolism, TCA cycle, ETS, ATP synthesis, amino acid metabolism, reactive oxygen species (ROS) detoxification, protein translation, and CoQ synthesis ([Figure 1H](#F1){ref-type="fig"}).

Functional Assessment of Lysine Malonylation Using a Comprehensive Mitochondrial Diagnostics Assay Platform {#S5}
-----------------------------------------------------------------------------------------------------------

The finding of widespread K*mal* in mitochondria of MCD-deficient muscle tissues, coupled with minimal changes in the mitochondrial proteome and metabolite profiles, provided a unique opportunity to assess the functional impact of these PTMs in a clinically relevant model with functional sirtuin activity. Moreover, the protein targets of malonylation overlapped substantially with those previously identified as hyperacylated in the context of genetically engineered sirtuin deficiencies and/or metabolic diseases. Thus, functional interrogation of the lysine malonylome identified herein was expected to unveil highly susceptible lysine acylation sites that confer important biological consequences. Because malonyl-CoA accumulation and lysine malonylation were greatest in heart tissue, we aimed to comprehensively evaluate the respiratory phenotype of heart mitochondria from MCD^M−/−^ versus control mice. To this end, we used a recently developed bioenergetics assay platform that evaluates respiratory fluxes and energy transfer in intact mitochondria working to regenerate ATP in the context of physiologically relevant energy demands and thermodynamic constraints ([@R20]). The platform leverages a modified version of the creatine kinase (CK) energetic clamp technique ([Figure 2A](#F2){ref-type="fig"}) to titrate and control the extra-mitochondrial ATP:ADP ratio (i.e., ΔG~ATP~; expressed in kcal/mol) to which isolated mitochondria are exposed. In simple terms, the assay platform evaluates how well a given population of mitochondria, energized by a specific combination of carbon fuels, responds to an energy challenge. Transition from a high to low ATP:ADP ratio mimics an increase in energy demand, akin to a transition between rest and exercise, and thereby serves as an *in vitro* "stress test." Analysis of the linear relationship between energy demand (ATP:ADP, ΔG~ATP~) and oxygen flux (*J*O~2~) allows for an estimation of respiratory "conductance" (i.e., reciprocal of resistance), wherein a steeper slope indicates greater sensitivity and improved kinetics. Both the absolute rates of oxygen consumption and respiratory sensitivity (slope) depend on energy gradients and fluxes controlled by three principal regulatory nodes: (1) the dehydrogenase enzymes, (2) the electron transport system (ETS) and, (3) ATP synthesis and transport, which together mediate the transfer of energy from that available in carbon substrates to electron potential energy (ΔG~redox~) to the proton motive force (PMF, ΔG~H+~) to the free energy of ATP hydrolysis (ΔG~ATP~) ([Figure 2B](#F2){ref-type="fig"}). To gain insight into the free energies that drive the transduction process, we combined the dynamic *J*O~2~ assays with parallel assessments of membrane potential (ΔΨ~m~), the primary contributor to the PMF, and NAD(P)H/NAD(P)^+^ redox state, along with *J*H~2~O~2~ as a measure of electron leak. A second arm of the assay platform serves to validate and/or further elucidate specific functional perturbations identified within each control node. This is accomplished through direct assessment of maximal ATP synthesis rates (*J*ATP) measured in intact mitochondria exposed to various substrates in the context of a hexokinase ADP clamp, as well as carbon flux though multiple DH enzyme activities (*J*NADH) performed in alamethicin permeabilized mitochondria that retain organization of protein complexes. Finally, Complex V activity is measured in mitochondrial lysates. Collectively, the entire suite of biochemical assays provides diagnostic information across wide-ranging pathways of the mitochondrial metabolic network.

Creatine Kinase Clamp Assays Reveal Subtle Bioenergetic Consequences of Lysine Malonylation {#S6}
-------------------------------------------------------------------------------------------

Use of different substrate combinations in isolated mitochondrial systems allows for the assessment of fluxes across specified spans of the energy transduction network, as each substrate combination results in a predicable activation of a subset of DH enzymes and ETS components. For example, saturating concentrations of pyruvate/malate (Pyr/M) will exclusively generate NADH from PDH, IDH3, and MDH2 and activate all three proton pumps within the ETS (e.g., CI, CIII, CIV). By contrast, succinate/rotenone (Succ/R) will restrict dehydrogenase flux to SDH, which generates FADH~2~ and activates only 2 of the 3 ETS proton pumps (e.g., CIII, CIV), resulting in decreased respiratory efficiency (P:O ratio; ATP generated per O~2~ consumed). For our experiments with heart mitochondria from MCD^fl/fl^ and MCD^M−/−^ mice, respiratory sensitivity was assessed in the presence of saturating doses of glutamate/malate (G/M), Pyr/M, octanoylcarnitine/malate (Oct/M), or Succ/R. Assessment of NAD-linked respiration supported by either G/M or Pyr/M revealed no differences in absolute *J*O~2~ or respiratory sensitivity between genotypes ([Figures 3A and 3E](#F3){ref-type="fig"}; G/M, Pyr/M). Respiratory sensitivities in the presence of Oct/M and Succ/R were also similar between genotypes ([Figures 3A and 3E](#F3){ref-type="fig"}; Oct/M, Succ/R); however, absolute *J*O~2~ in the presence of Oct/M was higher in MCD^M−/−^ heart mitochondria for the two lowest ATP-free energy conditions ([Figure 3A](#F3){ref-type="fig"}; Oct/M). Subsequent analysis of maximal respiratory capacity measured with saturating ADP and the long-chain fatty acid substrate, palmitoylcarnitine, were likewise indicative of adaptations that favored flux through beta-oxidation in the MCD^M−/−^ hearts ([Figure S5A](#SD1){ref-type="supplementary-material"}).

Although the *J*O~2~ plots were largely unremarkable, parallel assessment of ΔΨ and NAD(P)H/NAD(P)^+^ redox revealed evidence of genotype-specific mitochondrial remodeling. Thus, regardless of the substrate, ΔΨ trended toward a hyperpolarized state ([Figure 3B](#F3){ref-type="fig"}) and the relationship between *J*O~2~ and ΔΨ shifted rightward, such that mitochondria from MCD^M−/−^ mice were maintaining a greater (more negative) ΔΨ for a given rate of oxygen consumption ([Figure 3D](#F3){ref-type="fig"}). Despite the hyperpolarized ΔΨ, NAD(P)H/NAD(P)^+^ redox potential was unchanged ([Figure 3C](#F3){ref-type="fig"}). Taken together, these observations pointed toward more robust matrix DH fluxes and/or a potential flux limitation at node 3 ("ATP synthesis"). It should be noted that in these assays, ΔG~ATP~ is maintained by unlimited capacitance conferred by excess CK and creatine; thus, a phenotype of improved energy transfer efficiency (i.e., more negative ΔΨ for a given *J*O~2~) versus heightened resistance at the ATP synthesis node, are indistinguishable without further diagnostic information from the second arm of the platform.

MCD Deficiency Alters Activities of Multiple NAD-Linked Dehydrogenases and ATP Synthase {#S7}
---------------------------------------------------------------------------------------

To further probe the source of the hyperpolarized ΔΨ in Mcd^M−/−^ heart mitochondria, we next assessed substrate-specific maximal flux through ATP synthase in intact mitochondria, as well as fluxes through multiple NAD-linked DH enzymes using permeabilized mitochondria or mitochondrial lysates, both assayed in a single 96-well plate format. Results revealed consistent increases in pyruvate (PDH), alpha-ketoglutarate (AKGDH) and branched chain ketoacid (BCKDH) DH complexes in MCD^M−/−^ mitochondria, whereas glutamate DH (GDH), malate DH (MDH) and hydroxyacyl-CoA DH (HADHA) fluxes were unchanged ([Figure 3G](#F3){ref-type="fig"}; *J*NADH). Assessment of maximal *J*O~2~ using the substrate combination of pyruvate and carnitine, which restricts DH activation to PDH ([@R45]), confirmed increased PDH flux capacity in MCD^M−/−^ heart mitochondria ([Figure S5C](#SD1){ref-type="supplementary-material"}), which was explained in part by diminished phosphorylation of PDHE1A (S232 to a greater extent than S293), an inactivating PTM ([Figures S5D and S5E](#SD1){ref-type="supplementary-material"}). Because malonyl CoA serves as a precursor for mitochondrial lipoate ([@R16]), which is used for lipoylation of the E2 subunits of PDH, AKGDH, and BCKDH, we also assessed lipoylation status of these enzymes. However, analysis by immunoblot proved negative ([Figures S5F and S5G](#SD1){ref-type="supplementary-material"}). Direct measurement of *J*ATP synthesis in intact MCD^M−/−^ heart mitochondria revealed slightly decreased ATP synthesis capacity as compared to controls, but only in the presence of Oct/M ([Figure 3G](#F3){ref-type="fig"}; *J*ATP). Assessment of ATP synthase activity, measured in the reverse direction using mitochondrial lysates, revealed a \~15% decrease in enzyme activity ([Figure 3H](#F3){ref-type="fig"}), providing further evidence that CV might be contributing to a flux limitation in the MCD^M−/−^ mitochondria.

In sum, the combination of heightened DH capacity and a modest resistance at the ATP synthesis node could explain why MCD^M−/−^ heart mitochondria tend to maintain a hyperpolarized ΔΨ. Nonetheless, this level of ATP synthase inhibition was not sufficient to increase the rate of substrate-supported proton leak in the absence of ADP ([Figure S5B](#SD1){ref-type="supplementary-material"}) or electron leak measured under the energetic conditions of the CK clamp ([Figure 3F](#F3){ref-type="fig"}). Notably, this set of experiments evaluated respiratory and redox fluxes of \>15 metabolic enzymes identified as hypermalonylated proteins in the context of MCD deficiency, and yet the only evidence of impaired function was a modest 15% decline in maximal ATP synthase activity.

Loss of SIRT5 in the Heart Specifically Affects Succinate Dehydrogenase and ATP Synthase {#S8}
----------------------------------------------------------------------------------------

Next, we sought to evaluate a second genetic model characterized by lysine hyperacylation due to total body deletion of the mitochondrial deacylase *Sirt5*. Recent analysis of hearts from the same cohort of *Sirt5* null mice used for the current study showed that relative abundance of over \~2000 unique Ksuc sites in *Sirt5* KO hearts were increased by a magnitude ranging from 2- to 1,000-fold, with \~70% of those sites exceeding a 5-fold change ([@R26]). These mice have a baseline phenotype ([@R53]) as well as increased susceptibility to heart failure induced by transaortic constriction ([@R26]); thus, we expected Sirt5^−/−^ mitochondria would manifest clear bioenergetic insufficiencies. Contrary to this prediction, respiration profiles of mitochondria energized with the NAD-linked substrates, G/M and Pyr/M ([Figures 4A and 4E](#F4){ref-type="fig"}; G/M and Pyr/M) were unaffected by genotype, whereas absolute *J*O~2~ and respiratory sensitivities in the presence of FAD-linked substrates, Oct/M and Succ/R, were only modestly reduced in the Sirt5 KO group ([Figures 4A and 4E](#F4){ref-type="fig"}; Oct/M and Succ/R). In contrast to the MCD^M−/−^ model, membrane potential in *Sirt5*^−/−^ mitochondria was either unchanged or trended toward a more depolarized state, which reached significance only in the context of Succ/R ([Figure 4B](#F4){ref-type="fig"}). Accordingly, plotting *J*O~2~ against ΔΨ revealed a slight leftward shift, which was particularly evident in the presence of Succ/R ([Figure 4D](#F4){ref-type="fig"}), consistent with [@R74]. Analysis of the NAD(P)H/NAD(P)^+^ redox potential showed either no change or trends toward an increased (more reduced) redox energy charge in the *Sirt5*^−/−^ group ([Figure 4C](#F4){ref-type="fig"}), suggesting NAD-linked DH enzymes were not a source of flux resistance. Electron leak supported by Pyr/M was unaltered by genotype ([Figure 4F](#F4){ref-type="fig"}). Assays of NAD-linked DH enzyme fluxes and maximal *J*ATP ([Figure 4G](#F4){ref-type="fig"}; *J*ATP) rates produced largely negative results, with only one exception; HADHA flux was increased in Sirt5^−/−^ mitochondria ([Figure 4G](#F4){ref-type="fig"}; *J*NADH). Similar to that observed in the setting of MCD deficiency, maximal activity of ATP synthase measured in mitochondrial lysates was decreased \~15% in Sirt5^−/−^ mitochondria ([Figure 4H](#F4){ref-type="fig"}). Together, these data suggest that the primary impact of hypersuccinylation caused by SIRT5 ablation was a modest disruption of energetic fluxes mediated by protein complexes associated with or positioned in the inner mitochondrial membrane, including the FAD-linked DH complexes (SDH and ETFDH) and ATP synthase.

Loss of SIRT3 in the Heart Minimally Affects Mitochondrial Energetics, Despite Partial Inhibition of ATP Synthase {#S9}
-----------------------------------------------------------------------------------------------------------------

The most extensively studied mitochondrial sirtuin, the SIRT3 deacetylase, acts on the best characterized acyl modification, lysine acetylation (Kac). The cardiac acetylome of SIRT3-deficient mice was previously shown to encompass over 500 hyperacetylated peptides that exceeded abundance of that in the control group by a factor of 2- to 85-fold ([@R14]; [@R39]). Moreover, a pool of SIRT3 has been shown to bind ATP synthase ([@R70]). Thus, to compare the functional consequences of malonylation and succinylation with that of acetylation, the mitochondrial diagnostics workflow was applied to isolated heart mitochondria prepared from mice harboring heart- and muscle-specific deficiency of SIRT3 (Sirt3^M−/−^) as compared to transgenic littermates carrying the floxed alleles (Sirt3^fl/fl^). In Sirt3^M−/−^ mitochondria, respiratory sensitivities with all substrate combinations ([Figures 5A and 5E](#F5){ref-type="fig"}), as well as measurements of ΔΨ ([Figures 5B and 5D](#F5){ref-type="fig"}) and NAD(P)H/NAD(P)^+^ redox ([Figure 5C](#F5){ref-type="fig"}), were universally unaffected by genotype, with the exception of a slight hyperreduced redox state in the presence of G/M at an ATP free energy of −13.95 kcal/mol in Sirt3^M−/−^ mitochondria. Electron leak supported by Pyr/M was similarly unaffected by genotype ([Figure 5F](#F5){ref-type="fig"}). Measurements of *J*ATP synthesis revealed a slight increase in Sirt3^M−/−^ mitochondria energized with G/M ([Figure 5G](#F5){ref-type="fig"}; *J*ATP). Dehydrogenase fluxes were generally unaffected by genotype, with the exception of a slight decrease in PDH activity ([Figure 5G](#F5){ref-type="fig"}; *J*NADH). Of note, this decline in PDH maximal activity was insufficient to impair pyruvate-supported respiratory sensitivity. Despite a rather unremarkable respiratory phenotype across all substrates, the maximal activity of ATP synthase was again found to be decreased by \~15% in Sirt3^M−/−^ mitochondria ([Figure 5H](#F5){ref-type="fig"}). These findings suggest that absent of other bioenergetic perturbations, the modest decline in ATP synthase activity was insufficient to produce a phenotype in respiring mitochondria.

Analysis of the Complex V Acylome by Label-free Quantitative nLC-MS/MS {#S10}
----------------------------------------------------------------------

Given that partial loss of ATP synthase activity was observed in all three genetic models of hyperacylation (Figures [3H](#F3){ref-type="fig"}, [4H](#F4){ref-type="fig"}, and [5H](#F5){ref-type="fig"}), we questioned whether this effect might be mediated by acyl modification of one or more specific lysine residues common to each of the knockout lines analyzed. To test this possibility, the acyl-landscape of CV isolated by Blue Native-PAGE ([Figure S6A](#SD1){ref-type="supplementary-material"}) was evaluated in each mouse line using label-free quantitative nLC-MS/MS. This approach yielded 637 proteins identified and quantified across all samples--the top-five most abundant proteins corresponded to known subunits of the ATP synthase complex (ATP5A1, ATP5B, ATP5H, ATP5O, ATP5F1), with an average sequence coverage of 84% ([Table S2](#SD3){ref-type="supplementary-material"}). Approximately half of the acyl peptides identified and quantified in these samples (\~414 quantified peptides) map to known subunits of the ATP synthase complex (\~194 CV acyl-peptides; [Table S2](#SD3){ref-type="supplementary-material"}). The specific acyl modification found to be more abundant in each KO model aligned with expectations based on the genetic deficiency. That is, 8 malonylpeptides, 28 succinyl-peptides, and 23 acetyl-peptides were found to be increased (\> 1.5 log2 FC) above wild-type (WT) controls in samples from MCD-, SIRT5-, and SIRT3-deficient mitochondria, respectively ([Figures 6A--6C](#F6){ref-type="fig"}; [Table S2](#SD3){ref-type="supplementary-material"}) -- consistent with previous proteomics work identifying CV as a recurring acylation target across multiple biological models ([@R5]; [@R29]). Also noteworthy is that the five most robustly upregulated malonylation sites measured by label-free proteomics in semi-purified CV samples from MCD null compared to controls (ATP5L K55, ATP5F1 K225, ATP5O K162, ATP5B K124, ATP5A1 K531; [Table S2](#SD3){ref-type="supplementary-material"}) also exhibited hyperacylation (FDR \< 10%) in the discovery study using the TMT method ([Table S1](#SD2){ref-type="supplementary-material"}). Although the specific lysine residues found to be differentially acylated in each model mapped to similar protein subunits of CV, not a single overlapping lysine residue was found to be hyperacylated across all three models ([Figures 6D and 6E](#F6){ref-type="fig"}). Lack of overlap could be due in part to incomplete coverage of low abundant PTMs; however, the label-free proteomics methods used for this analysis incorporates algorithms for handling missing data to minimize sampling inconsistencies. In aggregate, these results suggest that the link between hyperacylation and diminished CV activity stems from a series of stochastic events on biochemically vulnerable lysine residues, rather than specifically targeted PTMs. Interestingly, ATP5A1 appeared highly susceptible to protein acylation, as 13 distinct lysine residues of this CV subunit were found to be hyperacylated above wild-type levels across all models ([Figure 6E](#F6){ref-type="fig"}).

Analysis of Mitochondrial Bioenergetics and Complex V Acylation in a Model of Diet-Induced Obesity {#S11}
--------------------------------------------------------------------------------------------------

Lastly, to compare the genetic models of hyperacylation to a physiologic perturbation known to broadly augment acyl-PTMs ([@R1]; [@R12]), we analyzed heart mitochondria harvested from mice fed a high fat (HF) diet for 8 weeks as compared to those fed standard chow (SC). Mitochondrial purity was similar between the chow versus HFD preparations ([Figures S6B and S6C](#SD1){ref-type="supplementary-material"}). Assessment of bioenergetic fluxes showed that the diet caused a generalized decrease in absolute *J*O~2~, regardless of substrate, and a slight reduction in respiratory sensitivity in the context of the NAD-linked substrates, G/M and Pyr/M ([Figures 7A and 7E](#F7){ref-type="fig"}). Membrane potentials ([Figures 7B and 7D](#F7){ref-type="fig"}) and redox profiles ([Figure 7C](#F7){ref-type="fig"}) were unremarkable; however, exposure to the high fat diet increased rates of electron leak, measured in the presence of Pyr/M and Oct/M ([Figure 7F](#F7){ref-type="fig"}). This effect, which was most prominent during the CK clamp assay, offers evidence that over-nutrition promotes mitochondrial H~2~O~2~ generation in the context of physiologically relevant energetic conditions.

The forgoing diet-induced changes in *J*O~2~ were accompanied by diminished activity of several DH enzymes ([Figure 7G](#F7){ref-type="fig"}; *J*NADH - PDH, AKGDH, GDH), consistent with slight reductions in NAD-linked supported *J*ATP ([Figure 7G](#F7){ref-type="fig"}; *J*ATP). Notably, the activity of ATP synthase was unaffected by diet ([Figure 7G](#F7){ref-type="fig"}; CV), even though we identified several acyl PTMs on the complex that were increased in abundance in the context of the HFD versus the standard chow condition ([Figure 7H](#F7){ref-type="fig"}). Compared to the genetic loss-of-function models, diet-induced changes in the lysine acylome of CV were less striking, ranging from 1- to 10-fold on a linear scale, and consisted mainly of acetyl-lysine modifications ([Table S2](#SD3){ref-type="supplementary-material"}). When comparing hyperacylated residues increased by the HFD (\> 1.5 log~2~ FC, relative to chow fed control) to those identified in the genetic models, we found only 5 lysine residues (Atp5a1 K103, K161, K498, and K531; Atp5b K259) in common. Thus, taken together, the impact of the diet on the overall mitochondrial respiratory phenotype was more remarkable than the sirtuin-deficient models, whereas its effect on the CV acyl-landscape was less impressive. These findings argue against a major role for acyl-PTMs in mediating diet-induced alterations in mitochondrial function.

DISCUSSION {#S12}
==========

Identification of thousands of unique, stress-responsive lysine acylation sites distributed throughout the mitochondrial proteome has been facilitated by the advent of high-resolution mass spectrometry instruments able to detect low stoichiometric PTMs ([@R29]). Although the breadth of these modifications is clearly impressive, a growing number of studies have concluded that the vast majority of acyl PTMs occur at occupancy rates of less than 1% ([@R46]; [@R66], [@R67]). Similar to most acyl-proteome studies, the current investigation measured and reported relative amounts of detected acyl-peptides rather than absolute quantities. Because the majority of mitochondrial-derived acyl-peptides detected by mass spectrometry are present at low occupancy, a significant change in the context of a KO model might have little biological relevance. Thus, although mitochondrial acyl-PTMs are emerging as ultra-sensitive biomarkers of mitochondrial acyl CoA content and/or flux, increasing recognition of their low stoichiometries has raised uncertainties about their roles as bona fide metabolic regulators ([@R18]; [@R50]; [@R67]). An alternative theory suggests sirtuins function as constitutively active quality control enzymes that preserve normal function of mitochondrial proteins by continuously repairing nonenzymatic acylation ([@R67]). This model implies that the stress sensitivities resulting from sirtuin deficiencies are a consequence of disrepair, which in turn compromises mitochondrial performance and metabolic resilience in the face of an energy challenge. Nonetheless, regardless of whether sirtuins act in a regulatory capacity and/or as a repair mechanism, convincing evidence that protein hyperacylation per se does indeed cause mitochondrial dysfunction in animal models is lacking.

Among the barriers to progress in this field is the lack of highly sensitive and widely accessible assay platforms for comprehensive assessment of carbon flux and energy transduction in isolated mitochondrial systems. For this reason, functional validation of acyl PTMs has relied heavily on enzyme activity assays, often comparing 0% versus near 100% stoichiometry modeled with mutant constructs designed to mimic the impact of a specific modification on protein biochemistry and/or structure ([@R8]; [@R10]; [@R17]; [@R24]; [@R25]; [@R55]; [@R56]; [@R57]; [@R58]; [@R69]; [@R71]; [@R75]). Moreover, functional validation is typically pursued using a candidate approach focused on one enzyme or pathway, assayed in isolation. The primary drawback of this approach is that it precludes assessment of potential cumulative effects and cooperativity ([@R4]), referring to the collective impact of multiple PTMs across the entire mitochondrial network.

By contrast, insights revealed by the present study stem from application of a recently developed bioenergetics assay platform designed to bridge the gap between molecular and functional mitochondrial phenomics ([@R20]). Compared to conventional respirometry methods, the multiplexed assay platform enables more comprehensive and less biased assessment of respiratory fluxes and energy transfer, performed under dynamic and more physiologically relevant energetic conditions. The collective results of these assays inform a "diagnostic tree" that localizes a given change in respiratory sensitivity and/or efficiency to one or more potential sites of regulation that can be further probed by more targeted assays ([Figure S7](#SD1){ref-type="supplementary-material"}). Application of this platform to a functional comparison of heart mitochondria from three distinct genetic models of mitochondrial hyperacylation revealed few or no deficits in a large number of respiratory and enzymatic fluxes, despite relative increases in acyl-PTM abundance that exceeded 100-fold. Moreover, the present study found very little evidence that NAD-linked DH fluxes per se were reduced in the settings of three distinct models of wide-ranging hyperacylation. One caveat to consider is that the assays employed did not measure Michaelis-Menten kinetics of specific enzymes. Still, a prominent theme emerging from this field of study is that increased acylation of the mitochondrial proteome--by malonylation, succinylation and/or acetylation--imposes negative feedback on DH enzymes involved in beta-oxidation ([@R11]; [@R53]), which in turn increases risk of hepatic and/or cardiac pathologies ([@R8]; Hirschey et al., 2010; [@R73]). These findings appear to conflict with those of the current study. However, the strongest evidence linking hyperacylation to diminished beta-oxidation comes from assays using radiolabeled palmitate and CO~2~ trapping performed in tissue homogenates or isolated mitochondria, or assessment of maximal respiration supported by fatty acid substrates. Importantly, diminished rates of CO~2~ production and/or maximal respiration could reflect flux limitations imposed at any number of steps throughout the mitochondrial energy transduction process, including complex V.

Interestingly, the only biochemical phenotype identified in all three of the genetic models tested in this study was a \~15% decline in ATP synthase activity, which corresponded with increased acylation of multiple lysine residues on protein constituents of CV. By comparison, in the context of a physiological model of mitochondrial acyl CoA accumulation (e.g., HFD), hyperacylation of CV was more modest and biochemical evidence of compromised ATP synthase activity and/or flux was lacking. In fact, contrary to that seen in the genetic models, the most prominent mitochondrial flux alteration caused by the HFD was elevated electron leak (i.e., *J*H~2~O~2~ emission). Although perturbations at the ATP synthesis control node (ANT or the phosphate carrier) could contribute to increased *J*H~2~O~2~ emission, the preponderance of evidence suggests that elevated electron leak induced by high fat feeding arises from alterations within the ETS ([@R3]). Moreover, assessment of the precise lysine residues found to be modified within CV, determined by label-free proteomics, failed to provide any evidence of specificity. These results are consistent with the idea that severe circumstances (e.g., genetic deficiencies) can push non-enzymatic lysine acylation to a level that interferes with the conformation of large protein complexes, particularly those associated with the inner mitochondrial membrane.

In summary, the present study sought to interrogate the functional relevance of cardiac acyl PTMs by applying a recently developed bioenergetics assay platform to a diverse set of mouse models harboring hyperacylation of mitochondrial proteins in heart. Taken at face value, our findings suggest the vast majority of mitochondrial acyl PTMs have little or no impact on respiratory function, which aligns with another recent report examining the role of Sirt3 in the pancreatic beta-cell ([@R50]). The primary consequence of robust proteome-wide increases in relative acyl-lysine occupancy rates within the matrix of cardiac mitochondria appears to be a modest decline in maximal activity of ATP synthase, due to the collective effects of several non-specific modifications. We consider several explanations for results that appear to contradict the prevailing narrative in this field. First, perhaps the stoichiometry of the PTMs in the models tested herein did not reach that occurring in the context of organ stress, such as heart failure or type 2 diabetes. Although possible, it seems unlikely that the stoichiometry of the most functionally relevant PTMs in the context of normal physiology or pathophysiology exceeds that which occurs in these complete loss-of-function models ([@R4]; [@R25]). Second, the cumulative impact of multiple non-enzymatic acylation events on ATP synthase, and other membrane-associated complexes, could prove detrimental as a "second hit" in the context of chronic metabolic disorders that severely compromise respiratory capacity. Third, the acyl-proteome landscape could impact interactions between the mitochondrial reticulum and other organelles and/or cellular constituents, which would not be captured in our assay system. Lastly, the findings raise the intriguing possibility that sirtuins evolved not to protect against the ravages of lysine acylation, but rather to act as rheostats that modulate carbon catabolism in proportion to overall flux through deacylation reactions, which consume NAD^+^ and therefore have the potential to impose feedback on specific DH enzymes by altering the local redox environment. This might explain how multiple low stoichiometric acyl PTMs that spread across enzymes and complexes of a specific metabolic pathway contribute to flux control without having a direct impact on protein conformation and function. To this point, deacylase flux would be similarly low in sirtuin-deficient mitochondria as compared to a control group with minimal lysine acylation, thereby producing a similar bioenergetic phenotype. Further examination of these possibilities now awaits future study.

STAR\*METHODS {#S13}
=============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S14}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Deborah M. Muoio (<debbie.muoio@duke.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S15}
--------------------------------------

All animal studies were approved by the Duke University Institutional Animal Care and Use Committee. C57Bl6 ES cells containing a conditionally targeted *Mlycd* gene were purchased from the KOMP (NIH-funded Knockout Mouse Project) repository at the University of California and homozygous C57BL6-LoxMlycd^tm^ (MCD-loxP) were generated by Dr. David Olson. Appropriate targeting of exon 2 of Mlycd was confirmed at both the 5′ and 3′ ends of the gene using long range PCR. Targeted ES cells were then injected into C57Bl6 blastocysts and implanted in pseudopregnant females. Offspring were genotyped for the presence of the 3′ loxP site. The final loxP-flanked, conditional *Mlycd* allele was ultimately generated after removing the Frt-flanked, lacZ:neomycin resistance cassette by crossing with Rosa26-Flp mice. Removal of the Frt-flanked lacZ:neomycin cassette was confirmed by PCR. The MCD floxed mice were bred to B6.FVB (129S4)-Tg(Ckmm-cre)^5Khn/J^ (The Jackson Laboratory; \#006475). This pairing and subsequent backcrossing to C57BL/6NJ mice produced the floxed control MCD^fl/fl^ and littermate muscle specific MCD knockout mice C57BL6/NJ-LoxMlycd^tmMuo/Duke^ mouse referred to herein as MCD^M−/−^.

Whole-body knockouts for *Sirt5* (Sirt5^−/−^) were described in [@R26]. Muscle specific *Sirt3* knockout mice (Sirt3^M−/−^) were generated by breeding *Sirt3* floxed mice (Sirt3^fl/fl^) with MCK-Cre mice and backcrossed onto the C57BL/6NJ background. For the high fat diet studies, C57BL/6NJ mice (purchased from Jackson Labs; Stock \#005304) were fed a 45% high fat (Research Diets; Cat\# D12451) or chow diet for a period of 8 weeks. All mice were housed in a temperature (22°C) and light controlled (12 hour light/12 hour dark) room and given free access to food and water. Male mice were used for all studies with an age range of 10-20 weeks for experiments investigating MCD, Sirt3 and Sirt5 deficiency. Experiments involving high fat fed C57BL/6NJ mice were performed on male mice ages 20-26 weeks. Unless otherwise stated, mice were fasted 1 hour and anesthetized with Nembutal (intraperitoneal injection; 100mg/kgBW) prior to tissue removal.

METHOD DETAILS {#S16}
--------------

### Chemical & Reagents: {#S17}

Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich. Potassium pyruvate was purchased from Combi-Blocks (QA-1116). Potassium NADP^+^ was purchased from Ark-Pharm (AK671068). Amplex Ultra Red, and Tetramethylrhodamine methyl ester (TMRM) were purchased from Thermo Fisher Scientific. Creatine kinase from rabbit muscle was purchased from Roche Life Science.

### Indirect Calorimetry {#S18}

The Comprehensive Lab Animal Monitoring System (CLAMS, Columbus Instruments) was used to determine rates of oxygen consumption (VO~2~), carbon dioxide production (VCO~2~) and respiratory exchange ratio (RER). Body weights of all mice were recorded prior to entering the metabolic chambers, as well as at the conclusion of the 36hr protocol. The first 12hrsof the protocol was considered an acclimatization period and thus data from this time period was not included in the final analysis. Whole body VO~2~ data were normalized to body weight. Access to food and water during these experiments was *ad libitum*.

### Mitochondrial Isolation {#S19}

Differential centrifugation was employed to prepare isolated mitochondria from skeletal muscle and heart. The following buffers were utilized for all isolations: Buffer A -- (phosphate buffered saline (pH = 7.4), supplemented with EDTA(10mM); Buffer B -- MOPS (50mM; pH = 7.1), KCl (100mM), EGTA (1mM), MgSO4 (5mM); Buffer C -- Buffer B, supplemented with bovine serum albumin (BSA; 2g/L). Skeletal muscle and heart were excised and immediately placed in ice-cold Buffer A. All tissues were minced and subjected to a 5-minute incubation on ice in Buffer A, supplemented with 0.05% trypsin. Following trypsin incubation, skeletal muscle and heart suspensions were centrifuged at 200 × G for 5-minutes at 4°C to remove trypsin. Tissue pellets were next suspended in Buffer C and then homogenized via a Teflon pestle and borosilicate glass vessel. Tissue homogenates were centrifuged at 500 × G for 10-minutes at 4°C. Supernatant from each tissue was then filtered through thin layers of gauze and subjected to an additional centrifugation at 10,000 × G for 10-minutes at 4°C. Mitochondrial pellets were washed in 1.4 mL of Buffer B, transferred to microcentrifuge tubes and centrifuged at 10,000 × G for 10-minutes at 4°C. Buffer B was aspirated from each tube and final mitochondrial pellets were suspended in 100-200 μL of Buffer B. Protein content was determined via the Pierce BCA protein assay. Functional assays involving isolated mitochondria were carried out in the following buffers; Buffer D -- Potassium-MES (105 mM; pH = 7.2), KCl (30 mM), KH~2~PO~4~ (10 mM), MgCl~2~ (5 mM), EGTA (1 m M), BSA (2.5 g/L); Buffer E -- HEPES (20 mM; pH = 8.0), KCl (100 mM), KH~2~PO~4~ (2.5 mM), MgCl~2~ (2.5 mM), Glycerol (1%).

### Metabolomics {#S20}

Whole-quadriceps skeletal muscle and heart were powdered under liquid N~2~, aliquoted, lysed in appropriate buffer \[(50% 2-propanol, 50% 0.1 M KH2 PO4, pH 4.45; 0.3 M perchloric acid (used for the measurement of malonyl-CoA)\] using a Tissue Lyzer II (QIAGEN), and subjected to metabolomics analysis using stable isotope dilution techniques. Amino acids and acylcarnitine were measured as described previously ([@R2]; [@R68]) using a Waters Acquity UPLC system equipped with a TQD and MassLynx 4.1 operating system. Acyl-CoA esters were extracted as 50 mg/ml tissue lysates, purified, and analyzed as described previously ([@R38]; [@R44]). Acyl-CoAs were analyzed by flow injection analysis using positive electrospray ionization on a Waters Xevo TQS, employing methanol/water (80:20%, v/v) containing 30 mM NH4 OH as the mobile phase. Malonyl-CoA was assessed as described previously ([@R21]) on a Waters Xevo TQ-S mass spectrometer coupled to Acquity UPLC system. Spectra were acquired in the multichannel acquisition mode monitoring the neutral loss of 507 atomic mass units (phosphoadenosine diphosphate) and scanning from m/*z* 750 to 1060. Heptadecanoyl-CoA was employed as an internal standard for long-chain and very-longchain CoA esters. CoAs were quantified using authentic saturated (C0-C18) and unsaturated (C16:1, C18:2, C18:1, and C20:4) acyl-CoA calibrators. All reported CoAs were within detection limits of the assay. Corrections for heavy isotope effects, mainly ^13^C, to the adjacent 2 spectral peaks were made empirically by referring to the observed spectra for the analytical standards.

### Preparation of mouse tissue for western blotting {#S21}

Flash frozen powdered quadriceps and heart tissue, as well as isolated mitochondrial pellets from each tissue were thawed on ice and homogenized in CelLytic M (Sigma-Aldrich; Cat\# C2978) supplemented with protease inhibitor cocktail and 10 mM nicotinamide using a motor-drive Potter-Elvehjem tissue grinder. Samples were centrifuged at 14,000 × g for 10 min at 4°C and the supernatant saved and frozen at −80°C until later analysis. Protein concentration was determined via the BCA method and the samples were diluted in CelLytic M buffer. Forty micrograms of protein sample were combined with 5× loading buffer and resolved by SDS-PAGE, transferred to nitrocellulose, blocked for \~1 hr in 5% milk prepared with TBS followed by western blotting with specific antibodies. Antibodies employed herein were: MCD (Proteintech; \#15265-1-AP), Sirt5 (see [Key Resources Table](#T1){ref-type="table"}), malonyl-lysine (Cell Signaling; \#14942), ETFDH (Abcam; \#ab126576), ETFα (Abcam; \#ab110316), Hadha (Abcam; \#ab203114), OXPHOS cocktail (Abcam; \#ab110413), Pdhe1α (Abcam; \#ab168379), phosphorylated Pdhe1α (Serine 232; \#AP1063, Serine 293; \#AP1062).

### Cell lysis, protein digestion, and peptide labeling for TMT proteomics: {#S22}

Skeletal muscle (approximately 20 mg of pulverized skeletal muscle (Quadriceps) and heart (left and right ventricles) tissue from MCD^fl/fl^ and MCD^MCK+/+^ mice (n = 3/group) were resuspended in ice-cold 8M Urea Lysis Buffer (8 M urea in 40 mM Tris, pH 8.0, 30 mM NaCl, 1 mM CaCl~2~, 1× cOmplete ULTRA mini EDTA-free protease inhibitor tablet, 10 mM Nicotinamide) and the samples were disrupted with a TissueLyzer (QIAGEN) for one minute at 30 Hz. The Samples were frozen on dry ice and thawed for three freeze-thaw cycles and further disrupted by sonication with a probe sonicator in three 5 s bursts (power setting of 3). Samples were centrifuged at 10,000 × g for 10 min at 4°C and the supernatant was retained. Protein concentration was determined by BCA, and equal amount of protein (500 μg, adjusted to 2.5mg/mL with Urea Lysis Buffer) from each sample were reduced with 5 mM DTT at 37°C for 30 min, cooled to room temperature, alkylated with 15 mM iodoacetamide for 30 min in the dark and unreacted iodoacetamide quenched by the addition of DTT up to 15 mM. Initial digestion was performed with Lys C (Wako Chemicals; Cat\# 125-05061; 1:100 w:w; 5 ug enzyme per 500 ug protein) for 4 hours at 37°C. Following dilution to 1.5M urea with 40 mM Tris (pH 8.0), 30 mM NaCl, 1 mM CaCl~2~, the samples were digested with trypsin (Promega; Cat\# V5113; 50:1 w/w, protein:enzyme) overnight at 37°C. The samples were acidified to 0.5% TFA and centrifuged at 4000 × g for 10 min at 4°C to pellet insoluble material. The supernatant containing soluble peptides was desalted on a 50 mg tC18 SEP-PAK Solid Phase Extraction (SPE) column (Waters; Cat\# WAT054955) and eluted once with 500 μL 25% acetonitrile/0.1% TFA and twice with 500 μL 50% acetonitrile/0.1% TFA. The 1.5 mL eluate was frozen and dried in a speed vac. The six samples from each tissue were re-suspended in 100 μL of 200 mM triethylammonium bicarbonate (TEAB), mixed with a unique 6-plex Tandem Mass Tag (TMT) reagent (0.8 mg re-suspended in 50 μL100% acetonitrile), and shaken for 4 hours at room temperature (ThermoFisher Scientific; Cat\# 90064). After samples were quenched with 0.8 μL 50% hydroxylamine and shaken for 15 additional minutes at room temperature, all six samples from each tissue were combined, frozen, and dried in a speed vac overnight. The mixtures from each tissue were re-suspended in \~1 mL of 0.5% TFA and subjected to SPE again as described above, but with a 100 mg tC18 SEP-PAK SPE column (Waters; Cat\# WAT023590). The eluate was vortexed and split into one aliquot containing \~5% of the total peptide mixture (150 μg) and a second aliquot containing \~95% (2.85 mg). Both aliquots were frozen and dried in a speed vac. The 150 μg aliquot of the "input" material was saved at −80°C for quantification of unmodified peptides and the 2.85 mg aliquot was used for enrichment of malonyl-peptides using immnoprecipitation.

### Malonylpeptide enrichment for TMT proteomics {#S23}

One hundred mg of concentrated Malonyl-Lysine \[Mal-K\] MultiMab Rabbit mAb mix (Cell Signaling \#14942) was coupled to 20 mL of Protein A/G agarose (ThermoFisher; Cat\# 20421) in PBS (pH 7.4) in a total volume of 500 μL with gentle rocking overnight at 4°C. The next day, antibody-coupled agarose was pelleted via centrifugation at 2000 × g for 30 s. The supernatant was discarded and pellet washed four times in 1 mL PBS. The dried down TMT-labeled peptides from each tissue were solubilized in 1.4 mL of IAP buffer (Cell Signaling Technolgy, \#9993) and incubated with the Mal-K antibody coupled agarose on a rotator overnight at 4°C. The next day, the antibody-peptide complexes were pelleted via centrifugation at 2000 × g for 30 s and washed 2 times in 1 mL of IAP buffer and three times with ultrapure de-ionized H~2~O. The peptides were eluted in 55 μL of 0.1% TFA for 10 min followed by a wash in 50 μL of 0.1% TFA and the supernatants (2000 × g, 30 s) from each elution were combined. The eluate was acidified to 0.5% TFA (and brought to a 1 mL volume), desalted on a 50 mg tC18 SEP-PAK SPE column as described above, frozen, and dried in a speed vac.

### nLC-MS/MS for TMT proteomics {#S24}

All samples were subjected to nanoLC-MS/MS analysis using either a nano-Acquity (Waters) or an EASY-nLC UPLC system (Thermo Fisher Scientific) coupled to a Q Exactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fischer Scientific) via a nano-electrospray ionization source. Prior to injection, malonylpeptide sample was resuspended in 12 μL 0.1% formic acid and was analyzed with at least technical duplicate runs. For each injection of 4 uL, the sample was first trapped on a Symmetry C18 20 mm × 180 μm trapping column (5 μl/min at 99.9/0.1 v/v water/acetonitrile), after which the analytical separation was performed over a 90-minute gradient (flow rate of 400 nanoliters/minute) of 3 to 30% acetonitrile using a 1.7 μm Acquity BEH130 C18 75 μm × 250 mm column (Waters Corp.), with a column temperature of 55°C. MS^1^ (precursor ions) was performed at 70,000 resolution, with an AGC target of 1×10^6^ ions and a maximum injection time (IT) of 60 ms. MS^2^ spectra (product ions) were collected by data-dependent acquisition (DDA) of the top 20 most abundant precursor ions with a charge greater than 1 per MS1 scan, with dynamic exclusion enabled for a window of 30 s. Precursor ions were filtered with a 1.2 m/*z* isolation window and fragmented with a normalized collision energy (NCE) of 30. MS2 scans were performed at 17,500 resolution, with an AGC target of 1×10^5^ ions and a maximum IT of 60 ms.

### Data analysis for TMT proteomics {#S25}

Proteome Discoverer 2.2 (PDv2.2) was used for raw data analysis, with default search parameters including oxidation (15.995 Da on M) as a variable modification and carbamidomethyl (57.021 Da on C) and TMT6plex (229.163 Da on peptide N-term and K) as fixed modifications, and 2 missed cleavages (full trypsin specificity). To assess labeling efficiency as a quality control measure, the input fraction was re-searched with N-terminal TMT as a variable modification, confirming N-terminal labeling of 79 and 94% of all PSMs from the skeletal muscle and heart samples, respectively. Malonyl-enriched fraction runs added malonylation (86.00039 Da on K) as a variable modification and changed TMT to a variable modification on K (remaining fixed on peptide N-term) and increased maximum missed trypsin cleavage sites to 4. Considering each data type (malonyl, input) separately, PSMs from each search algorithm were filtered to a 1% FDR and PTM site localization probabilities were determined. PSMs were grouped to unique peptides while maintaining a 1% FDR at the peptide level and using a 90% localization threshold for PTMs. Peptides from all fractions (malonyl, input) were grouped to proteins together using the rules of strict parsimony and proteins were filtered to 1% FDR using the Protein FDR Validator node of PD2.2. Reporter ion intensities for all PSMs having co-isolation interference below 0.5 (50% of the ion current in the isolation window) and an average S/N \> 2.5 for reporter ions were summed together at the peptide and protein level, but keeping quantification for each data type (malonyl, input) separate. Peptides shared between protein groups were excluded from protein quantitation calculations.

### Statistical analysis for TMT proteomic experiment {#S26}

Protein and peptide groups tabs in the PDv2.2 results were exported as tab delimited .txt. files, and analyzed with an in-house *Python* module based on a previously described workflow ([@R41]). First, peptide group reporter intensities for each peptide group in the input material were summed together for each TMT channel, each channel's sum was divided by the average of all channels" sums, resulting in channel-specific loading control normalization factors to correct for any deviation from equal protein/peptide input into the six sample comparison. Reporter intensities for peptide groups from the malonylpeptide runs, and for proteins from the input fraction runs were divided by the tissue-specific loading control normalization factors for each respective TMT channel. Analyzing the malonylpeptide, and protein datasets separately (for each tissue), all loading control-normalized TMT reporter intensities were converted to log~2~ space, and the average value from the six samples was subtracted from each sample-specific measurement to normalize the relative measurements to the mean. For MCD^fl/fl^ and MCD^M−/−^ comparisons (n = 3) within each tissue, condition average, standard deviation, p value (p, two-tailed Student's t test, assuming equal variance), and adjusted p value (P~*adjusted*~, Benjamini Hochberg FDR correction) were calculated ([@R6]; [@R37]). For protein-level quantification, only Master Proteins--or the most statistically significant protein representing a group of parsimonious proteins containing common peptides identified at 1% FDR--were used for quantitative comparison. Malonylpeptide measurements were calculated both alone (referred to as ***abundance***) and with normalization to any change in the corresponding Master Protein (referred to as ***relative occupancy***), calculated by subtracting Log~2~ Master Protein values from PTM-containing peptide quantitation values on a sample-specific basis.

### Blue Native-PAGE {#S27}

Mitochondrial pellets were lysed in 1 × Native gel electrophoresis sample buffer (BisTris; pH = 7.2, NaCl, glycerol and Ponceau S; Thermo \#BN2003), supplemented with 10 mM nicotinamide,1x protease inhibitor cocktail and 6% digitonin. Samples were left on ice for \~20 minutes and then spun down at 10,000 × G for 30 minutes at 4°C. Supernatants were transferred to fresh micro-centrifuge tubes and protein content was determined using the BCA assay. Prior to loading samples onto Native gels, G-250 Coomassie sample additive (Thermo \#BN2004) was added to each sample. Native-PAGE was performed by loading 50 ug of mitochondrial protein onto a 4%-16% BisTris Native gel (Thermo; BN1004). Following PAGE, proteins were fixed and de-stained (40% methanol, 10% acetic acid) for \~10 minutes at room temperature.

### CV Acylome Sample Prep {#S28}

Mitochondrial pellets were lysed in 1 × Native gel electrophoresis sample buffer (BisTris; pH = 7.2, NaCl, glycerol and Ponceau S; Thermo \#BN2003), supplemented with 10 mM nicotinamide, 1× protease inhibitor cocktail and 6% digitonin. Samples were left on ice for \~20 minutes and then spun down at 10,000 × G for 30 minutes at 4°C. Supernatants were transferred to fresh micro-centrifuge tubes and protein content was determined using the BCA assay. Prior to loading samples onto Native gels, G-250 Coomassie sample additive was added to each sample. Native-PAGE was performed by loading 50 ug of mitochondrial protein onto a 4%--16% BisTris Native gel. Following PAGE, proteins were fixed and de-stained (40% methanol, 10% acetic acid) for \~10 minutes at room temperature. Following Blue Native-PAGE, the bands corresponding to CV were excised using a scalpel and chopped into 1.5^2^ mm cubes. Gel pieces were washed 1 × for 15 minutes in 100 μLs of 1:1 Acetonitrile (ANC;100%):100mM ammonium bicarbonate (AmBIC). Solution was removed and gel pieces were washed in 100 μLs of 100% ACN. Following ACN removal, gel pieces were rehydrated and reduced in 100 mM AmBIC, supplemented with 10mM dithiothreitol (DTT) for 30 minutes at 55°C. Solution was removed and replaced with 100mM AmBIC, supplemented with 55mM iodoacetamide and samples were incubated for 30 minutes at room-temperature protected from light. Gel pieces were washed 1 × for 15 minutes in 100 μLs of 1:1 ANC/AmBIC and then again in 100 μLs of 100% ACN. Following removal of ACN, gel pieces were rehydrated in 100 μLs of digestion buffer (50 mM AmBIC, 5 mM CaCl~2~, 10 ng/μL trypsin) and incubated overnight at 37°C. Following a brief spin-down, supernatant (containing all peptides) from each sample was placed in fresh 1.7ml tube. Gel pieces were incubated for 15 minutes in 50% ACN, 0.3% formic acid, as well as 80% ACN, 0.3% formic acid. Supernatants from these incubations were combined with the original supernatant. Samples were flash frozen and then speed vacuumed overnight. Dried down peptides were reconstituted in 10 μLs of 5% ACN, 0.1% TFA (pH \< 3) and desalted using C18 Ziptips (Millipore; Cat\# ZTC18S096) according to manufacturer instructions. Following sample elution, samples were once again dried in a speed vac.

### CV Acylome nLC-MS/MS {#S29}

Samples were resuspended in 20 μLs of 0.1% formic acid and subjected to nLC-MS/MS in a randomized order (with blanks in between) as described above, but with the following changes: For nLC using an EASY-nLC UPLC system (Thermo Fisher Scientific), sample injections of 8.5 μL were first trapped on an Acclaim PepMap 100 C18 trapping column (3 um particle size, 75 μm × 20 mm) with 22 uL of solvent A (0.1% FA) at a variable flow rate dictated by max pressure of 500 Bar, after which the analytical separation was performed over a 105 minute gradient (flow rate of 300 nL/minute) of 5 to 40% solvent B (90% ACN, 0.1% FA) using an Acclaim PepMap RSLC C18 analytical column (2 um particle size, 75 μm × 500 mm column (Thermo Fischer Scientific) with a column temperature of 55°C. MS^1^ used 70,000 resolution, 3×10^6^ AGC target, and 100 ms maximum IT. MS^2^ used DDA (top 20), dynamic exclusion for 30 s, 1.2 *m/z* isolation window, NCE of 27, 17,500 resolution, 1×10^5^ AGC target, and 100 ms maximum IT. Raw data were processed in PDv2.2 using the Byonic search engine (Protein Metrics, Inc.) as a node ([@R7]). To generate a focused database for subsequent acyl-peptide quantification, data were searched against the UniProt mouse proteome database indicated above. Following generation of the focused database using Byonic, all searches included the following four variable modifications (all set as "common"): oxidation (M) and acylation of lysine (monoisotopic additions to K in parentheses) with an acetyl (42.010565 Da), malonyl (86.00039 Da), or succinyl (100.016044 Da) group. Searches for the diet study additional included crotonyl (68.026215), glutaryl (114.031694) and propionyl (56.026215) modifications on K, but these PTMs were not included in post-search data reduction. Fixed modification of carbamidomethyl (C) was selected. The maximum number of missed cleavages was set at 2 and enzyme specificity was trypsin. PSMs were filtered to a 1% false discovery rate (FDR) in PDv2.2 based on the target-decoy search results from Byonic. PSMs were grouped to peptides maintaining 1% FDR at the peptide level and peptides were grouped to proteins using the rules of strict parsimony. Proteins were filtered to 1% FDR using the Protein FDR Validator node of PD2.2. Peptide quantification was done using the MS1 precursor intensity. Imputation was performed via low abundance resampling. Quantitation for each acylpeptide identified was normalized to the relative abundance of the corresponding protein within each sample to control for differences in protein expression, sample loading, and LC-MS performance

### Mitochondrial Respiratory Control {#S30}

High-resolution O~2~ consumption measurements were conducted using the Oroboros Oxygraph-2K (Oroboros Instruments). All experiments were carried out at 37°C in a 2 mL reaction volume. Steady-state oxygen consumption rates (*J*O~2~) ranging from near state 4 (i.e., non-phosphorylating) all the way to \~95% of maximal state 3 were sequentially determined within individual experiments using a modified version of the creatine energetic clamp technique ([@R22]; [@R43]). In this assay, the free energy of ATP hydrolysis (ΔG'~ATP~) can be calculated based on known amounts of creatine (Cr), phosphocreatine (PCr) and ATP in combination with excess amounts of creatine kinase (CK) and the equilibrium constant for the CK reaction (i.e., K~CK~). Calculation of ΔG'~ATP~ was performed according to the following formula: $$\Delta G_{ATP}^{\prime} = \Delta G_{ATP}^{\prime \circ} + RT\ln\frac{\left\lbrack {Cr} \right\rbrack\left\lbrack P_{i} \right\rbrack}{\left\lbrack {PCr} \right\rbrack\left\lbrack K_{CK}^{\prime} \right\rbrack}$$ where ΔG'°~ATP~ is the standard apparent transformed Gibbs energy (under a specified pH, ionic strength, free magnesium and pressure), R is the gas constant (8.3145 J/kmol) and T is temperature in kelvin (310.15). Given that experiments were performed via sequential additions phosphocreatine, both the ΔG"°~ATP~ and *K*'~CK~ were determined at each titration step based on the changes in buffer ionic strength and free magnesium, as previously described ([@R23]; [@R59]). Calculation of ΔG'~ATP~ at each titration point was performed using a recently developed online tool (<https://dmpio.github.io/bioenergetic-calculators/>).

Buffer for all assays was Buffer D, supplemented creatine (Cr; 5 mM), phosphocreatine (PCr; 1 mM) and creatine kinase (CK; 20 U/mL). Buffer D for Experiments with Sirt3^fl/fl^ also included ATP (5 mM) prior to the addition of substrates. To begin, isolated mitochondria (0.025 mg/mL) were added to assay buffer, followed by the addition of respiratory substrates then ATP (5 mM). The following substrate conditions were tested: \[Octanoyl-carnitine/Malate -- (Oct/M; 0.2/2.5 mM), Glutamate/Malate -- (G/M; 10/2.5 mM), Pyruvate/Malate-(Pyr/M; 5/2.5 mM), Succinate/Rotenone-(Succ/R; 10/0.005 mM)\]. Following substrate additions, sequential additions of PCr to 3, 6, 9, 12, 15mM were performed to gradually slow *J*O~2~ back toward baseline. For experiments in which a near state 4 rate were determined, ATP was omitted from the initial buffer and added after the addition of respiratory substrates. Plotting the calculated ΔG'~ATP~ against the corresponding *J*O~2~ reveals a linear force-flow relationship, the slope of which represents the conductance/elasticity of the entire respiratory system under specified substrate constraints.

### Mitochondrial membrane potential (ΔΨ) and NAD(P)H/NAD(P)^+^ Redox: {#S31}

Fluorescent determination of ΔΨ and NAD(P)H/NAD(P)^+^ were carried out simultaneously via a QuantaMaster Spectrofluorometer (QM-400; Horiba Scientific). Determination of ΔΨ via TMRM was done as described previously ([@R54]), via taking the fluorescence ratio of the following excitation/emission parameters \[Ex/Em, (572/590 nm)/(551/590 nm)\]. The 572/551nm ratio was then converted to millivolts via a KCl standard curve performed in the presence of valinomycin ([@R33]). NAD(P)H excitation/emission parameters were 340/450nm. All experiments were carried out at 37°C in a 0.2 mL reaction volume. Bufferforall assays was Buffer D, supplemented with creatine (Cr; 5mM), phosphocreatine (PCr; 1 mM), creatine kinase (CK; 20 U/mL) and TMRM (0.2 mM). To begin, isolated mitochondria (0.1 mg/mL) were added to the assay buffer, followed by the addition of respiratory substrates (Oct/M, G/M, Pyr/M, Succ/R), adenosine triphosphate (5 mM), and then sequential PCr additions to a final of 3, 6, 9,12, 15, 18, 21,24, 30mM. Following the final PCr addition, cyanide (4 mM) was added to induce a state of 100% reduction within the NAD(P)H/NAD(P)^+^ couple. The fluorescence (Ex/Em, 340/450 nm) signal recorded in the presence of mitochondria alone without respiratory substrates was used as the 0% reduction state for the NAD(P)H/NAD(P)^+^ couple. NAD(P)H/NAD(P)^+^ during the entire experiment was expressed as a percentage reduction according to the following formula: % Reduction = (F−F~0%~)/(F~100%~−F~0%~).

### Mitochondrial JH~2~O~2~ Emission: {#S32}

Mitochondrial H~2~O~2~ emission was measured fluorometrically via the Amplex Ultra Red (AUR)/horseradish peroxidase (HRP) detection system (Ex:Em 565:600 nm). Fluorescence was monitored via a QuantaMaster Spectrofluorometer (QM-400, Horiba Scientific). For each experiment, resorufin fluorescence was converted to pmoles H~2~O~2~ via an H~2~O~2~ standard curve generated under identical substrate conditions as employed for each protocol. All experiments were carried out at 37°C in a 0.2 mL reaction volume. Bufferforall assays was Buffer D, supplemented with creatine (Cr; 5 mM), phosphocreatine (PCr; 1 mM), creatine kinase (CK; 20 U/mL), AUR (10 μM), HRP (1 U/mL) and superoxide dismutase (20U/mL). To begin, isolated mitochondria (0.1 mg/mL) were added to assay buffer, followed by the addition of respiratory substrates (Oct/M and Pyr/M), auranofin (0.1 μM), adenosine triphosphate (5 mM), and then sequential PCr additions to a final of 6, and 15 mM. The percentage of electron leak is calculated by dividing the rate of H~2~O~2~ production by the corresponding O~2~ consumption rate measured under identical conditions and expressed as a percentage (% Leak = *J*H~2~O~2~/*J*O~2~). Of note, the *J*H~2~O~2~ rates used in the calculation were generated in the presence of auranofin; however, the corresponding *J*O~2~ assays did not contain auranofin, as the inhibitor does not impact respiratory conductance ([@R20]).

### JATP Synthesis {#S33}

Rates of ATP synthesis were determined as described previously ([@R36]). Buffer for the assay was Buffer D, supplemented with glucose (5 mM), hexokinase (1 U/mL), glucose-6-phosphate dehydrogenase (G6PDH; 2 U/mL), NADP^+^ (2 mM) and ADP (0.2 mM). Assay buffer (200 μL) was loaded into individual wells of a 96-well plate, followed by isolated mitochondria (2 μg/well). The assay was initiated with the addition of respiratory substrates following a \~5 minute pre-incubation at 37°C in the absence of substrates to deplete endogenous metabolites. In the assay, NADPH and ATP are produced in a 1:1 stoichiometry and thus *J*ATP was determined via monitoring the NADPH auto-fluorescence (Ex:Em 340/450nm) signal. Fluorescence values were converted to pmoles of ATP via an ATP standard curve. The following substrate conditions were tested in parallel for each assay \[Oct/M; 0.2/2.5 mM, G/M; 10/2.5 mM, Pyr/M; 5/2.5 mM, Succ/R; 10/0.005 mM\].

### JNADH Production {#S34}

Rates of NADH production were determined as described previously ([@R19]). Buffer for the assays was Buffer D, supplemented with alamethicin (0.03 mg/mL), rotenone (0.005 mM) and NAD^+^ (2 mM) or NADP^+^ (2 mM). For experiments designed to assess *J*NADH from the pyruvate dehydrogenase complex (PDH), the alpha-ketoglutarate dehydrogenase complex (AKGDH) and the branched-chain keto-acid dehydrogenase complex (BCKDH) the followed cofactors were included in the assay: coenzyme A (0.1 mM) and thiamine pyrophosphate (0.3 mM). Assay buffer (200 μL) was loaded into individual wells of a 96-well plate, followed by isolated mitochondria (2-60 μg/well). The assay was initiated with the addition of enzymatic substrates. In the assay, NADH is determined via auto-fluorescence (Ex:Em 340/450nm). Fluorescence values were converted to pmoles of NADH via an NADH standard curve. The following substrates were tested in parallel for each assay \[pyruvate (5 mM), alpha ketoglutarate (10 mM), α-keto-β-methylvalerate (5 mM), glutamate (10 mM) and malate (5 mM)\].

### CV Activity Assay {#S35}

Mitochondrial lysates for the assay were prepared via dilution of the final isolated mitochondrial suspensions in CelLytic M at a protein concentration of 2mg/mL. Buffer for the assay was Buffer E, supplemented with lactate dehydrogenase/pyruvate kinase (10 U/mL), phosphoenoyl-pyruvate (5 mM), rotenone (0.005 mM) and NADH (0.2 mM). Assay buffer (200 μL) was loaded into individual wells of a 96-well plate, followed by mitochondrial lysate (2 μg/well). Assays were done in the absence and presence of oligomycin (0.005 mM) in order to calculate the oligomycin-sensitive rates of ATP hydrolysis. The assay was initiated with the addition of ATP (5 mM). In the assay, NADH oxidation and ATP hydrolysis occur at a 1:1 stoichiometry and thus CV activity (pmoles of ATP/sec/mg) was determined via tracking the degradation in the NADH auto-fluorescence (Ex:Em 376/450nm) signal upon ATP addition. Fluorescence values were converted to pmoles of NADH via an NADH standard curve.

### Hydroxyacyl-CoA Dehydrogenase Activity {#S36}

Mitochondrial lysates for the assay were prepared via dilution of the final isolated mitochondrial suspensions in CelLytic M at a protein concentration of 2 mg/mL. Buffer for the assay was Buffer E, supplemented with rotenone (0.005 mM) and NADH (0.2 mM). Assay buffer (200 μL) was loaded into individual wells of a 96-well plate, followed by mitochondrial lysate (5 μg/well). The assay was initiated with the addition of acetoacetyl-CoA (0.2 mM). The activity of hydroxyacyl-CoA dehydrogenase was determined via tracking the degradation in the NADH auto-fluorescence (Ex:Em 340/450 nm) signal upon acetoacetyl-CoA addition. Fluorescence values were converted to pmoles of NADH via an NADH standard curve.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S37}
---------------------------------------

Data are presented as mean ± SEM. Statistical analysis was performed using t tests or one-way ANOVA with Student-Newman-Keuls methods for analysis of significance among groups. Figures were generated using GraphPad Prism (Version 7.0). The level of significance was set at p \< 0.05. Statistical details of each experiment are located in the figure legends. Unless otherwise stated, the number of mice per experiment is represented by "N."

DATA AND SOFTWARE AVAILABILITY {#S38}
------------------------------

All raw data for proteomics experiments is available online using accession number "PXD011375" for Proteome Xchange ([@R13]) and accession number "JPST000507" for jPOST Repository ([@R48]).
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![Loss of MCD in Muscle Increases Mitochondrial Malonyl-CoA and Promotes Lysine Malonylation\
(A) Volcano plot depicting acyl carnitine (red dots), acyl CoA (blue dots), and amino acid (gray dots) relative abundance in heart of MCD^fl/fl^ (WT) and MCD^M−/−^ (KO) mice. Data are expressed as log~2~-fold change (KO/WT).\
(B) Malonyl CoA abundance.\
(C) Malonyl carnitine abundance is expressed as a percentage of MCD^fl/fl^ heart tissue.\
(D) MCD expression in liver and heart tissues in whole-cell lysates compared to a mitochondrial-enriched fraction assessed via immunoblot.\
(E) Malonyl proteomics workflow.\
(F) Volcano plot depicting relative abundance of malonyl-peptides identified in heart tissue from MCD^fl/fl^ and MCD^M−/−^ mice. Red and black dots indicate peptides matched to mitochondrial or non-mitochondrial proteins, respectively. The size of each point is scaled according to its false discovery rate (FDR) such that larger points have lower FDRs.\
(G) Volcano plot depicting changes in the heart proteome between genotypes. The data point corresponding to MCD is circled.\
(H) hypermalonylated protein targets identified in both heart and skeletal muscle of MCD-deficient mice. Shading of each protein represents the number of hypermalonylated lysine residues (P~adjusted~ \< 0.1).\
Data are mean ± SEM. (A--C) n = 6/group, (D) n = 2/group, and (F and G) n = 3/group and were analyzed by Student"s t test. \*p \< 0.05; \*\*p \< 0.001; \*\*\*p \< 0.0001. n represents biological replicates.](nihms-1520907-f0001){#F1}

![Mitochondrial Diagnostics Workflow\
(A) Isolated and intact mitochondria from heart tissue were used for measuring rates of ATP synthesis (*J*ATP) or permeabilized (+Alamethicin) for rates of NADH generation (*J*NADH), both performed with multiple substrates in a 96-well plate format. Rates of oxygen consumption (*J*O~2~) and respiratory sensitivity were assessed using the Oroboros-O2K system and the creatine kinase (CK) energetic clamp technique. Parallel measures of membrane potential (ΔΨ), redox potential (NAD(P)H/NAD(P)^+^, and *J*H~2~O~2~ emission were obtained via spectrofluorometric assays using a QuantaMaster Spectrofluorometer.\
(B) Mitochondrial energy transduction is modeled as a series of interconnected energy transfer steps that regulate ATP-free energy (ΔG~ATP~). In node \#1, respiratory fuels activate specific dehydrogenase (DH) enzymes that transfer the chemical energy in carbon fuels to electron potential energy (ΔG~redox~), experimentally assessed via the fluorescent measurement of the NAD(P)H/NAD(P)^+^ redox state. In node \#2, the 'Electron Transport System" (ETS) converts energy available ΔG~redox~ to proton potential energy (ΔG~H+~) harnessed in the electrochemical proton motive force (PMF). Efficiency of energy transfer at node \#2 is assessed by fluorescent measurement of ΔΨ, the primary contributor to the PMF. In node \#3, the energy available in ΔG~H+~ drives the synthesis and transport of ATP via the ATP synthase complex (CV) and the adenine nucleotide translocase (ANT). Mitochondrial *J*O~2~ reflects the flux of the proton current at Complex IV of the ETS and thus serves as the experimental measurement of node \#3.](nihms-1520907-f0002){#F2}

![Comprehensive Assessment of Mitochondrial Energy Fluxes in the Setting of MCD Deficiency\
(A--H) Isolated mitochondria from hearts of MCD^fl/fl^ versus deficient MCD^M−/−^ mice were used for all experiments.\
(A--C) Relationship between mitochondrial (A) *J*O~2~, (B) mitochondrial ΔΨ, and (C) NAD(P)H/NAD(P)^+^ redoxstate versus Gibb"s energy of ATP hydrolysis (ΔG~ATP~) in mitochondria energized with G/M, Pyr/M, Oct/M, and Succ/Rot.\
(D) Mitochondria *J*O~2~ plotted against ΔΨ in the presence of G/M, Succ/R, and Oct/M.\
(E) Calculated slopes from the linear portions of the data depicted in (A). Linear portions are located to the left of the dotted line on each graph.\
(F) Mitochondria electron leak, expressed as a percentage (*J*H~2~O~2~/*J*O~2~ × 100 = % electron leak) in the presence Pyr/M and Oct/M.\
(G) Quantified rates of ATP synthesis (*J*ATP) in intact mitochondria energized with G/M, Pyr/M, Oct/M, and Succ/R; rates of NADH production (*J*NADH) by various enzymes were measured in permeabilized mitochondria. Data are expressed as the percentage of MCD^fl/fl^ controls.\
(H) Quantified CV activity are expressed as the percentage of fl/fl controls.\
Data are mean ± SEM, n = 8--12/group and were analyzed by Student"s t test. \*p \< 0.05; \*\*p \< 0.001; \*\*\*p \< 0.0001. n represents biological replicates.](nihms-1520907-f0003){#F3}

![Comprehensive Assessment of Mitochondrial Energy Fluxes in the Setting of Sirt5 Deficiency\
(A--H) Isolated mitochondria from hearts of Sirt5 control (Sirt5^+/+^) versus deficient (Sirt5^−/−^) mice were used for all experiments.\
(A--C) Relationship between mitochondrial (A) *J*O~2~, (B) mitochondrial ΔΨ, and (C) NAD(P)H/NAD(P)^+^ redoxstate versus Gibb"senergy of ATP hydrolysis (ΔG~ATP~) in mitochondria energized with G/M, Pyr/M, Oct/M, and Succ/Rot.\
(D) Mitochondria *J*O~2~ plotted against ΔΨ in the presence of G/M, Succ/R, and Oct/M.\
(E) Calculated slopes from the linear portions of the data depicted in (A). Linear portions are located to the left of the dotted line on each graph.\
(F) Mitochondria electron leak, expressed as a percentage (*J*H~2~O~2~/*J*O~2~ × 100 = % electron leak), in the presence Pyr/M in Sirt5^−/−^ heart mitochondriacompared to Sirt5^+/+^.\
(G) Quantified rates of ATP synthesis (*J*ATP) in intact mitochondria energized with G/M, Pyr/M, Oct/M, and Succ/R; rates of NADH production (*J*NADH) by various DH enzymes were measured in permeabilized mitochondria. Data are expressed as the percentage of MCD^fl/fl^ controls.\
(H) Quantified CV activity.\
(G and H) Data expressed as the percentage of fl/fl controls. Dotted red line represents 100% of Sirt5^+/+^ controls. Data are mean ± SEM, n = 8/group and were analyzed by Student"s t test. \*p \< 0.05. n represents biological replicates.](nihms-1520907-f0004){#F4}

![Comprehensive Assessment of Mitochondrial Energy Fluxes in the Setting of Sirt3 Deficiency\
(A--H) Isolated mitochondria from hearts of Sirt3-competent (Sirt3^fl/fl^) versus Sirt3-deficient (Sirt3^M−/−^) mice were used for all experiments.\
(A--C) Relationship between mitochondrial (A) *J*O~2~, (B) mitochondrial ΔΨ, and (C) NAD(P)H/NAD(P)^+^ redox state versus Gibb"senergy of ATP hydrolysis (ΔG~ATP~) in mitochondria energized with G/M, Pyr/M, Oct/M, and Succ/Rot.\
(D) Mitochondria *J*O~2~ plotted against ΔΨ in the presence of G/M, Succ/R, and Oct/M.\
(E) Calculated slopes from the linear portions of the data depicted in (A). Linear portions are located to the left of the dotted line on each graph.\
(F) Mitochondria electron leak, expressed as a percentage (*J*H~2~O~2~/*J*O~2~ × 100 = % electron leak), in the presence Pyr/M in Sirt3-deficient heart mitochondria compared to WT.\
(G) Quantified rates of ATP synthesis(*J*ATP) in intact mitochondria energized with G/M, Pyr/M, Oct/M, and Succ/R; rates of NADH production (*J*NADH) byvarious DH enzymes were measured in permeabilized mitochondria. Data are expressed as the percentage of MCD^fl/fl^ controls.\
(H) Quantified CV activity.\
(G and H) Data expressed as the percentage of fl/fl controls. Dotted red line represents 100% of fl/fl controls. Data are mean ± SEM. n = 8/group and were analyzed by Student"s t test. \*p \< 0.05; \*\*p \< 0.001; \*\*\*p \< 0.0001. n represents biological replicates.](nihms-1520907-f0005){#F5}

![Comparisons of the CV Acylome across Multiple Loss-of-Function Models Reveals a Stochastic Pattern of Acylation\
(A--C) Volcano plots depicting relative abundance of malonyl-peptides (red dots), succinyl-peptides (blue dots), and acetyl-peptides (green dots) identified within CV proteins isolated from hearts of mice with deficiency of (A) MCD, (B) Sirt5, or (C) Sirt3, expressed relative to fl/fl or +/+ controls.\
(D) Overlapping acyl-peptides (color-coded for malonyl, succinyl, or acetyl) from each genetic model found to be elevated above controls (\> 1.5 log~2~ FC).\
(E) Graphical depiction of the identified lysine acylation events on CV across all three models. The color of each subunit is indicated in the table to the left. OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane. This figure was generated using the bovine crystal structure of ATP synthase (PDB: 5ARA) ([@R76]).](nihms-1520907-f0006){#F6}

![Comprehensive Assessment of Mitochondrial Energy Fluxes in the Setting of Overnutrition\
(A--H) Isolated mitochondria from hearts of C57BL/6NJ mice fed a high-fat (HF) or standard chow (SC) diet were used for all experiments.\
(A--C) Relationship between mitochondrial (A) *J*O~2~, (B) mitochondrial ΔΨ, and (C) NAD(P)H/NAD(P)^+^ redox state versus Gibb"senergy of ATP hydrolysis (ΔG~ATP~) in mitochondria energized with G/M, Pyr/M, Oct/M, and Succ/Rot.\
(D) Mitochondria *J*O~2~ plotted against ΔΨ in the presence of G/M, Pyr/M, and Succ/R.\
(E) Calculated slopes from the linear portions of the data depicted in (A). Linear portions are located to the left of the dotted line on each graph.\
(F) Mitochondria electron leak, expressed as a percentage (*J*H~2~O~2~/*J*O~2~ × 100 = % electron leak), in the presence Pyr/M and Oct/M.\
(G) Quantified rates of ATP synthesis(*J*ATP) in intact mitochondria energized with G/M, Pyr/M, Oct/M, and Succ/R; rates of NADH production (*J*NADH) by various DH enzymes measured in permeabilized mitochondria, as well as CV activity. Data expressed as the percentage of SC controls. The dotted red line represents 100% of WT.\
(H) Volcano plots depicting the relative abundance of malonyl-peptides (red dots), succinyl-peptides (blue dots), and acetyl-peptides (green dots) identified within CV proteins from HF mice relative to SC controls.\
Data are mean ± SEM. (A--G) n = 11/group and (H) n = 5/group and were analyzed by Student"s t test. \*p \< 0.05; \*\*p \< 0.001; \*\*\*p \< 0.0001. n represents biological replicates.](nihms-1520907-f0007){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                                                              SOURCE                                                                                        IDENTIFIER
  -------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  Antibodies                                                                                                                                                                                                                     
  Total Rodent OXPHOS WB Antibody Cocktail                                                                                         Abcam                                                                                         Cat\# ab1110413, RRID:AB_2629281
  Malonyl-Lysine \[Mal-K\] MultiMab Rabbit mAb mix                                                                                 Cell Signaling                                                                                Cat\# 14942
  ETFDH                                                                                                                            Abcam                                                                                         Cat\# ab126576, RRID: AB_11141444
  ETFA                                                                                                                             Abcam                                                                                         Cat\# ab110316, RRID: AB_10865517
  HADHA                                                                                                                            Abcam                                                                                         Cat\# ab54477, RRID: AB_2263836
  PDH E1α                                                                                                                          Abcam                                                                                         Cat\# ab110330, RRID: AB_10858459
  Lipoic Acid                                                                                                                      Millipore Sigma                                                                               Cat\# 437695, RRID: AB_212120
  Pan anti-malonyllysine antibody                                                                                                  PTM Biolabs                                                                                   Cat\# PTM-901, RRID: AB_2687947
  MLYCD                                                                                                                            Proteintech Group                                                                             Cat\# 15265-1-AP, RRID: AB_2146403
  Sirt5                                                                                                                            Generous gift from Leonard Guarente (Massachusetts Institute of Technology, Cambridge, MA).   
  PDH E1α (pSer^232^)                                                                                                              Millipore Sigma                                                                               Cat\# AP1063
  PDH E1α (pSer^293^)                                                                                                              Millipore Sigma                                                                               Cat\# AP1062
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                                                                  
  Tris salt of phosphocreatine                                                                                                     Millipore Sigma                                                                               Cat\# P1937; CAS\# 108321-17-1
  Tris salt of ATP                                                                                                                 Millipore Sigma                                                                               Cat\# A9062; CAS\# 102047-34-7
  Potassium pyruvate                                                                                                               Combi-Blocks                                                                                  Cat\# QA-1116; CAS\# 4151-33-1
  Potassium NADP+                                                                                                                  Ark-Pharm, Inc                                                                                Cat\# AK671068
  Creatine kinase from rabbit muscle                                                                                               Millipore Sigma                                                                               Cat\# 10736988001
  Amplex Ultra Red Reagent (AUR)                                                                                                   ThermoFisher Scientific                                                                       Cat\# A36006
  CelLytic M                                                                                                                       Millipore Sigma                                                                               Cat\# C2978
  Tetramethylrhodamine methyl ester (TMRM)                                                                                         ThermoFisher Scientific                                                                       Cat\# T668
  Phosphoenoyl-pyruvate                                                                                                            Millipore Sigma                                                                               Cat\# 10108294001; CAS\# 4265-07-0
  Auranofin                                                                                                                        Millipore Sigma                                                                               Cat\# A6733;
  Oligomycin                                                                                                                       Millipore Sigma                                                                               Cat\# 75351; CAS\# 579-13-5
  Rotenone                                                                                                                         Millipore Sigma                                                                               Cat\# R8875; CAS\# 83-79-4
  Potassium cyanide                                                                                                                Millipore Sigma                                                                               Cat\# 60178; CAS\# 151-50-8
  Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)                                                                      Millipore Sigma                                                                               Cat\# C2920; CAS\# 370-86-5
  Peroxidase from horseradish (HRP)                                                                                                Millipore Sigma                                                                               Cat\# P8375; CAS\# 9003-99-0
  Superoxide dismutase (SOD)                                                                                                       Millipore Sigma                                                                               Cat\# S9697; CAS\# 9054-89-1
  Glucose-6-phosphate Dehydrogenase (G6PDH)                                                                                        Millipore Sigma                                                                               Cat\# G6378; CAS\# 9001-40-5
  Malate dehydrogenase (MDH)                                                                                                       Millipore Sigma                                                                               Cat\# 442610-M; CAS\# 9001-64-3
  Pyruvate Kinase/Lactic Dehydrogenase enzymes from rabbit muscle                                                                  Millipore Sigma                                                                               Cat\# P0294
  Hexokinase                                                                                                                       Millipore Sigma                                                                               Cat\# H4502; CAS\#9002-07-7
  Trypsin from porcine pancreas (Trypsin)                                                                                          Millipore Sigma                                                                               Cat\# T4799; CAS\# 9001-51-8
  Creatine Monohydrate                                                                                                             Millipore Sigma                                                                               Cat\# C3630; CAS\# 6020-87-7
  Octanoyl-L-carnitine                                                                                                             Millipore Sigma                                                                               Cat\# 50892; CAS\# 25243-95-2
  Malic acid (Malate)                                                                                                              Millipore Sigma                                                                               Cat\# M1000; CAS\# 97-67-6
  Glutamic acid (Glutamate)                                                                                                        Millipore Sigma                                                                               Cat\# G1501; CAS\# 6382-01-0
  Succinic acid (Succinate)                                                                                                        Millipore Sigma                                                                               Cat\# S3674; CAS\# 110-15-6
  α-ketoglutaric acid (AKG)                                                                                                        Millipore Sigma                                                                               Cat\# K1750; CAS\# 328-50-7
  3-Methyl-2-oxopentanoic acid (α-keto-β-methylvalerate)                                                                           Millipore Sigma                                                                               Cat\# 198978; CAS\# 3715-31-9
  Isocitrate                                                                                                                       Millipore Sigma                                                                               Cat\# 58790; CAS\# 20226-99-7
  Adenosine diphosphate (ADP)                                                                                                      Millipore Sigma                                                                               Cat\# A5285; CAS\# 72696-48-1
  Tetraphenylphosphonium (TPP^+^)                                                                                                  Millipore Sigma                                                                               Cat\# 218790; CAS\# 2001-45-8
  NADH                                                                                                                             Millipore Sigma                                                                               Cat\# N7004; CAS\# 104809-32-7
  Nicotinamide adenine dinucleotide (NAD^+^)                                                                                       Millipore Sigma                                                                               Cat\# N1636; CAS\# 53-84-9
  L-Aspartic acid (Aspartate)                                                                                                      Millipore Sigma                                                                               Cat\# A9256; CAS\# 56-84-8
  Acetoacetyl-CoA                                                                                                                  Millipore Sigma                                                                               Cat\# A1625; CAS\# 1420-36-6
  Coenzyme A                                                                                                                       Millipore Sigma                                                                               Cat\# C3019; CAS\# 18439-24-2
  Thiamine pyrophosphate                                                                                                           Millipore Sigma                                                                               Cat\# C8754; CAS\# 154-87-0
  Pyridoxal 5′-phosphate                                                                                                           Millipore Sigma                                                                               Cat\# P9255; CAS\# 853645-22-4
  1× cOmplete ULTRA mini EDTA-free protease inhibitor tablet                                                                       Roche                                                                                         Cat\# 5892791001
  Nicotinamide                                                                                                                     Sigma                                                                                         Cat\# N3376
  iodoacetamide                                                                                                                    Sigma                                                                                         Cat\# l1149-5G
  DL-Dithiothreitol                                                                                                                Fluka                                                                                         Cat\# 43819-1G
  Lysyl Endopeptidease, Mass Spectrometry Grade (Lys C)                                                                            Wako Chemicals                                                                                Cat\# 125-05061
  Sequencing-Grade Modified Trypsin                                                                                                Promega                                                                                       Cat\# PAV5113
  Sixplex Tandem Mass Tag (TMT) isobaric labeling kit                                                                              Thermo Fischer Scientific                                                                     Cat\# 90061
  Protein A/G agarose                                                                                                              Thermo Fischer Scientific                                                                     Cat\# 20421
  IAP buffer                                                                                                                       Cell Signaling Technolgy                                                                      Cat\# 9993
  Native gel electrophoresis sample buffer                                                                                         Thermo Fischer Scientific                                                                     Cat\# BN2003
  G-250 Coomassie sample additive                                                                                                  Thermo Fischer Scientific                                                                     Cat\# BN2004
  Experimental Models: Organisms/Strains                                                                                                                                                                                         
  C56BL/6NJ mice                                                                                                                   The Jackson Laboratory                                                                        Stock\# 005304
  Data and Software Availability                                                                                                                                                                                                 
  Jupyter notebook containing the adjustment calculations interspersed with procedural descriptions needed to calculate ΔG~ATP~.   N/A                                                                                           <https://github.com/dmpio/bioenergetic-calculators/blob/master/jupyter_notebook/creatine-kinase-clamp.ipynb>
  Web-based ΔG~ATP~ calculator                                                                                                     N/A                                                                                           <https://dmpio.github.io/bioenergetic-calculators/ck_clamp/>
  Proteome Discoverer 2.2                                                                                                          Thermo Fisher Scientific                                                                      Cat\# IQLAAEGABSFAKJMAUH
  Raw LC-MS/MS proteomics data                                                                                                     ^D^roteome Xchange jPOST                                                                      Accession PXD011375 Accession JPST000507
  Other                                                                                                                                                                                                                          
  QuantaMaster Spectrofluorometer                                                                                                  Horiba Scientific                                                                             Cat\# QM-400
  Glass screw neck autosampler vials                                                                                               Waters                                                                                        Cat\# 600000671cv
  4-16% BisTris Native gel                                                                                                         Thermo Fischer Scientific                                                                     Cat\# BN1004
  C18 ZipTips                                                                                                                      Millipore                                                                                     Cat\# ZTC18S096
  tC18 SEP-PAK Solid Phase Extraction columns (50 mg and 100mg)                                                                    Waters                                                                                        Cat\# WAT054960 Cat\# WAT036820
  Pierce high pH Reversed-Phase Peptide Fractionation Kit                                                                          Thermo Fischer Scientific                                                                     Cat\# 84868
  Pierce Quantitative Colorimetric Peptide Assay                                                                                   Thermo Fischer Scientific                                                                     Cat\# 23275
  Pierce BCA Protein Assay Kit                                                                                                     Thermo Fischer Scientific                                                                     Cat\# 23225

###### Highlights

-   Interrogating the role of lysine acylation in regulating mitochondrial quality

-   Comparison of three disparate genetic models of hyperacylated heart mitochondria

-   A mitochondrial diagnostics platform evaluates \>60 distinct energetic fluxes

-   Substantial shifts in the acyl-lysine landscape minimally affect bioenergetics
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